Multiple Myeloma, Refractory Clinical Trials

12 recruiting

Multiple Myeloma, Refractory Trials at a Glance

13 actively recruiting trials for multiple myeloma, refractory are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in West Hollywood, Hangzhou, and Ashkelon. Lead sponsors running multiple myeloma, refractory studies include Oncotherapeutics, Zhejiang University, and Essen Biotech.

Browse multiple myeloma, refractory trials by phase

Treatments under study

About Multiple Myeloma, Refractory Clinical Trials

Looking for clinical trials for Multiple Myeloma, Refractory? There are currently 12 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Multiple Myeloma, Refractory trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Multiple Myeloma, Refractory clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 113 of 13 trials

Recruiting
Phase 2

A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

Multiple Myeloma, Refractory
Karyopharm Therapeutics Inc127 enrolled16 locationsNCT04414475
Recruiting
Not Applicable

Universal CAR-T Cell Therapy for MM

Multiple MyelomaMultiple Myeloma in RelapseMultiple Myeloma, Refractory
Bioray Laboratories6 enrolled1 locationNCT07248176
Recruiting
Not Applicable

Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma

Multiple MyelomaMultiple Myeloma in RelapseMultiple Myeloma, Refractory+2 more
University Health Network, Toronto144 enrolled1 locationNCT06485076
Recruiting
Phase 2

HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM

Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Duke University27 enrolled1 locationNCT06822972
Recruiting
Phase 1

A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies

NeoplasmsMultiple Myeloma in RelapseMultiple Myeloma, Refractory+2 more
Technische Universität Dresden16 enrolled1 locationNCT05836896
Recruiting
Phase 1Phase 2

Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma

Multiple MyelomaMultiple Myeloma in RelapseMultiple Myeloma, Refractory+1 more
Essen Biotech60 enrolled1 locationNCT07032129
Recruiting
Phase 2

Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis

Multiple Myeloma, Refractory to Standard TreatmentMultiple Myeloma, RelapsedLight Chain Amyloidosis
Polina Stepensky180 enrolled1 locationNCT06971380
Recruiting
Phase 2

All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma

Multiple Myeloma in RelapseMultiple Myeloma, Refractory
The First Affiliated Hospital of Xiamen University25 enrolled1 locationNCT06158412
Recruiting
Phase 2

A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Oncotherapeutics39 enrolled2 locationsNCT06115135
Recruiting
Phase 1

A Trial of Selinexor, Ruxolitinib and Methylprednisolone

Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Oncotherapeutics30 enrolled1 locationNCT06225310
Recruiting
Phase 1

LMY-920 for Treatment of Relapsed or Refractory Myeloma

Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Luminary Therapeutics30 enrolled1 locationNCT05546723
Recruiting
Early Phase 1

APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Zhejiang University36 enrolled1 locationNCT04657861
Recruiting
Early Phase 1

CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies

Acute Lymphoblastic Leukemia, in RelapseMultiple Myeloma in RelapseMultiple Myeloma, Refractory+3 more
Zhejiang University120 enrolled1 locationNCT04603872